BioCentury
ARTICLE | Regulation

Xenical: Biochemical 'jaw-wiring'

May 19, 1997 7:00 AM UTC

WASHINGTON - The FDA will make a final decision on the marketing application for Hoffmann-La Roche Inc.'s Xenical obesity drug within a month, according to James Bilstad, chief of metabolic drugs at the agency.

Bilstad's comment followed a unanimous recommendation for Xenical's approval last week by the Endocrinologic and Metabolic Drugs Advisory Committee...